Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer

Journal of Biomedical Research

Volumn 27, Issue 3, 2013, Pages 220-230

  Sun, Wenze ^a   Song, Liping ^a   Ai, Ting ^a   Zhang, Yingbing ^a   Gao, Ying ^a   Cui, Jie ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cyclin D1; MET; MET gene copy number; Non small cell lung cancer (NSCLC); Prognosis

Indexed keywords

CYCLIN D1; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; GENE; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MET GENE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84890264356     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.27.20130004     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106- 30.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
3. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-25.
4. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009; 63: 169-79.
5. Comoglio PM, Boccaccio C. Scatter factors and invasive growth. Semin Cancer Biol 2001; 11: 153-65.
6. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev 2002; 2: 289-300.
7. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007; 98: 1006-13.
8. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87: 1063-69.
9. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479 -88.
10. Okuda K , Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008; 99: 2280-85.
11. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010; 5: 305-13.
12. Chen YT, Chang JWC, Liu HP, Yu TF, Chiu YT, Hsieh JJ, et al. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without prior tyrosine kinase inhibitor treatment. J Thorac Oncol 2011; 6: 2027-35.
13. Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, et al. c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas. J Thorac Oncol 2012; 7: 331-9.
14. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012; 7: 340-7.
15. Mac Lachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5: 127-56.
16. Caputi M, Groeger AM, Esposito V, Dean C, De Luca A, Pacilio C, et al. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol 1999; 20: 746-50.
17. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474: 230-4.
18. Choi J, Park SY, Joo CK. Hepatocyte growth factor induces proliferation of lens epithelial cells through activation of ERK1/2 and JNK/SAPK. Invest Ophthalmol Vis Sci 2004; 45: 2696-704.
19. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, et al. Knockdown of cMet by adenovirusdelivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005; 4: 157784.
20. Machide M, Hashigasako A, Matsumoto K, Nakamura T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 2006; 281: 8765-72.
21. Gugger M, Kappeler A, Vonlanthen S, Altermatt H J, Ris H J, Lardinois D, et al. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer 2001; 33: 229-39.
22. Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204: 101-9.
23. Khoury T, Alrawi S, Ramnath N, Li Q, Grimm M, Black J, et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung can-cer. Clin Lung Cancer 2009; 10: 58-66.
24. Esposito V, Baldi A, De Luca A, Tonini G, Vincenzi B, Santini D, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. J Clin Pathol 2005; 58: 734-9.
25. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, et al. Deregulation of p27 and cyclin D1/ D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 2010; 5: 1325- 36.
26. Saitoh G, Sugio K, Ishida T, Sugimachi K. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Rep 2001; 8: 737-43.
27. Kosacka M, Piesiak P, Kowal A, Golecki M, Jankowska R. Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res 2011; 30: 101-7.
28. Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009; 20: 298-304.
29. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104: 20932-7.
30. Onozato R, Kosaka T, Kuwano H, Yoshitaka S, Yasushi Y, Tetsuya M. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thoracic Oncol 2009; 4: 5-11.
31. Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and cMET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009; 15: 651-8.
32. Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 2008; 3: 331-9.
33. National Comprehensive Cancer Network (2004) NCCN clinical practice guidelines in oncology: non-small cell lung cancer guideline 2004. http://www.nccn.org
34. Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol 2009; 100: 708-12.
35. Tsao MS, Liu N, Chen JR,Pappas J, Ho J, To C, et al. Differential expression of MET/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998; 20: 1-16.
36. Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004; 90: 1555-62.
37. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 2005; 11: 6177-85.
38. Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, et al. High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012; 27: 197-207.
39. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27: 1667-74.
40. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T,Oyama T, et al. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 2010; 5: 591-6.
41. Ayeda AK, Adesina A; Prognostic significance of cyclin D1 expression in resected stage I, II non-small cell lung cancer in Arabs. Interact Cardiovasc Thorac Surg 2006; 5: 47-51.